Full results & analysis
Available in the Gosset platform where reported.
01
Overview
Phase 2, open-label, single-arm trial of 6MW3211 in clear cell renal cell carcinoma (ccRCC), sponsored by Mabwell. Primary endpoint: Objective Response Rate at 24 months. Status: unknown.
02
Design
1 arm- Study design
- Non-randomizedOpen-label
6MW3211
6MW3211 injection, 30mg/kg, Q2W
03
Who it enrols
Patients with advanced clear cell renal cancer who have failed at least one prior line of therapy, have measurable disease, and ECOG status 0-1.
04
Endpoints
Primary
Objective Response Rate
Secondary
Safety and Tolerability
Beyond the preview
Go deeper on NCT05440045.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05440045.